← Back to Clinical Trials
Recruiting Phase 4 NCT05850091

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

Trial Parameters

Condition Coronary Artery Disease
Sponsor Massachusetts General Hospital
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 200
Sex ALL
Min Age 40 Years
Max Age 75 Years
Start Date 2023-12-07
Completion 2026-05-01
Interventions
RosuvastatinColchicinePlacebo

Brief Summary

The goal of this double-blind randomized controlled trial is to determine how treatment with high intensity statin, low-dose colchicine, and their combination modulates progression and composition of coronary atherosclerosis in individuals with high polygenic risk for coronary artery disease.

Eligibility Criteria

Inclusion Criteria: * Males and females between 40 and 75 years of age capable and willing to provide informed consent * Participant has high CAD PRS as defined on a clinical test * Participant with subclinical atherosclerosis defined as plaque visible on CCTA and causing \<70% luminal stenosis Exclusion Criteria: * Participant with a history of cardiovascular disease, defined by a diagnosis of coronary artery disease, peripheral artery disease, or cerebrovascular disease * Participant with a history of Liver disease (cirrhosis, active hepatitis, or severe hepatic disease) or any of the following recent lab results and determined to be non-transient: alanine aminotransferase greater than 3 times the upper limit of normal or total bilirubin greater than 2 times the upper limit of normal (unless due to Gilbert syndrome) * Participant with estimated glomerular filtration rate \<60 mL/min/1.73 m2 or creatinine greater than 2 times the upper limit of normal * Patient with history of an alle

Related Trials